J&J has received US FDA approval for Tremfya (guselkumab), to treat moderately to severely active Crohn's disease (CD) in ...

The approval introduces the therapy ... In January, 2025, J&J’s nasal spray Spravato secured a label expansion from the FDA for use as a single agent in adults with major depressive disorder ...

New Directions Mental Health's Greensburg clinic now offers SPRAVATO®, an FDA-approved nasal spray for fast relief from treatment-resistant depression. GREENSBURG, PA, UNITED STATES, March 26 ...

only approves the drug ketamine for use in general anesthetics. However, Medicare may cover the drug Spravato, which contains esketamine. This is an FDA-approved drug that derives from ketamine ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

J&J's Spravato was FDA-approved in January as the only monotherapy for adults with treatment-resistant major depressive disorder. Feel unsure about the market’s next move? Copy trade alerts from ...

In terms of the newest collaboration, the health care professionals said they decided that having all the services under one ...

The FDA has cleared Auvelity (dextromethorphan ... That status goes to Johnson & Johnson's Spravato (esketamine), which was approved in March 2019 and is administered as a nasal spray twice ...

In 2019, the FDA approved Spravato for patients with treatment-resistant depression to take along with another antidepressant. Speaker 9: All-new tonight, a controversial new treatment for depression.